Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Navigating The Post-Election Landscape: Life Sciences & Healthcare

    Now that the US election has passed, industry leaders will need to understand the policy priorities for the Biden Administration and 117th Congress
    United StatesFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Article

    New Analysis Of Correlation Of Talc And Mesothelioma Published

    A recently published medical journal article analyzed talc exposure in the development of mesothelioma.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Clyde & Co
    Clyde & Co
Article

New Nanoparticle Targets Acidic Environment Associated With The Presence Of Cancer Cells

Researchers at MIT have developed a new drug-delivery nanoparticle that is unique in its ability to successfully target the acidic environment found near almost all types of cancer cells.
United StatesFood, Drugs, Healthcare, Life Sciences
Day Pitney LLP
Day Pitney LLP
  • Article

    New York State Files Suit Against E-Cigarette Manufacturer

    The State of New York has filed a civil lawsuit against JUUL Labs, alleging deceptive and illegal practices involving their flavored e-cigarette products
    United StatesFood, Drugs, Healthcare, Life Sciences
    Clyde & Co
    Clyde & Co
  • Article

    Newly Launched: Goodwin's Laboratory Developed Tests Resource Page

    Our Life Sciences Regulatory & Compliance team has launched a new resource page, keeping you up-to-date on the latest regulatory developments affecting laboratory developed tests (LDTs).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Podcast

    Outlook 2017 for Health Care and Life Sciences—What to Expect from HHS, FDA and Congress (podcast)

    What impact will the incoming Trump administration have on the 2017 health care and life sciences regulatory outlook?
    United StatesFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    Outlook For Life Sciences M&A: Industry Drivers Still Strong

    In a recent GEN Edge article, Duane Morris partner Rebecca Guzman discussed the state of M&A activity in the life sciences.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Duane Morris LLP
    Duane Morris LLP
  • Article

    Outlook Therapeutics Secures FDA Approval For LYTENAVA™

    Outlook Therapeutics has achieved a significant regulatory milestone with FDA approval of LYTENAVA™, the first ophthalmic formulation of bevacizumab specifically developed for treating neovascular age-related macular degeneration. While bevacizumab has been used off-label in retina care through repackaged oncology formulations, this marks the first FDA-approved version designed specifically for intravitreal ophthalmic use, with the product expected to receive 12 years of exclusivity under the BPCIA.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Personalized Multiplex Test On Market

    A multiplex test that can analyze tumors for over 200 genes is now available from Foundation Medicine Inc., the Wall Street Journal reported today.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    Physician Reimbursement - Will Medicare Cuts Continue?

    On November 2, 2023, the Centers for Medicare and Medicaid Services (CMS) released the 2024 Physician Fee Schedule Final Rule (Final Rule), which finalized changes to payment...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Ankura Consulting Group LLC
    Ankura Consulting Group LLC
  • Article

    Pippins Quoted In Natural Products Insider On FDA Regulatory Issues

    She also discussed how the recent departure of Commissioner Scott Gottlieb from the FDA will impact the consumer products industry.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Article

    Podcast: SaMD Series: What Should Life Sciences Companies Know?

    Software as a Medical Device – also referred to as SaMD – is one of the fastest growing innovations in the medical device industry.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • Article

    Potential Breakthrough In The Treatment of Ovarian Cancer Using Nanoparticle Therapeutic Carriers

    A preclinical study performed by scientists at the University of North Carolina and Duke University has demonstrated the potential for the treatment of ovarian cancer using nanotechnology.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Day Pitney LLP
    Day Pitney LLP
  • Article

    Prefilled Syringe Presentation Of GSK's SHINGRIX Receives Positive CHMP Opinion

    On October 21, 2025, GSK announced that the European Medicine Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") adopted a positive opinion for the shingle vaccine SHINGRIX...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Privacy Issues In The Sharing Of Genetic Information 1 Oct 2014

    Low cost sequencing of a patient’s genome and advances in the interpretation of a patient’s genetic information is promised to transform the delivery of health care.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    QMSR: Welcomed By The Industry, But Lacking In Practicality

    On March 2, 2022, FDA hosted a public Device Good Manufacturing Practice Advisory Committee meeting, where the Committee discussed the proposed rule titled "Medical Devices: Quality System Regulation Amendments."
    United StatesFood, Drugs, Healthcare, Life Sciences
    Morrison Foerster
    Morrison Foerster
  • Article

    Recent Biosimilar Commercialization Developments

    Meitheal and Tonghua Dongbao will be jointly responsible for development and supply, with the expectation of achieving FDA approval in 2026.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Regulation Of Synthetic Biology Under The Nagoya Protocol

    This December, representatives from 196 nations will come to Mexico for the 13th meeting of the Convention on Biological Diversity (CBD).
    United StatesFood, Drugs, Healthcare, Life Sciences
    WilmerHale
    WilmerHale
  • Podcast

    Regulatory Horizons: Cybersecurity And FDA Regulated Companies (Podcast)

    Cybersecurity is no longer just an IT or privacy issue. For FDA regulated companies, it's a patient safety issue, a product quality issue, and increasingly a regulatory enforcement issue.
    United StatesFood, Drugs, Healthcare, Life Sciences
    BakerHostetler
    BakerHostetler
  • Podcast

    Regulatory Horizons: What Life Sciences Companies Should Know About The BIOSECURE Act (Podcast)

    Today's topic is a big one: the BIOSECURE Act, signed into law on December 18, 2025, as part of the FY 2026 National Defense Authorization Act.
    United StatesFood, Drugs, Healthcare, Life Sciences
    BakerHostetler
    BakerHostetler
  • Showing 521–540 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics